Basiliximab

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Basiliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetCD25
Clinical data
Trade namesSimulect
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D
  • US: B (No risk in non-human studies)
    ATC code
    Pharmacokinetic data
    Elimination half-life7.2 days
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    ChEMBL
    Chemical and physical data
    FormulaC6378H9844N1698O1997S48
    Molar mass143801.3 g/mol g·mol−1
     NY (what is this?)  (verify)

    Uses

    Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[2]

    Mechanism of action

    Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]

    Chemistry

    It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4]

    History

    It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[5]

    References and notes
    1. MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
    2. Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.
    3. Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211.
    4. Basiliximab label
    5. Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.